Post Polycythemia Vera Myelofibrosis
Post-polycythemia vera myelofibrosis is a rare bone marrow disorder that occurs after polycythemia vera, a type of blood cancer.
The condition leads to fibrous tissue development in the bone marrow, causing anemia, fatigue and splenomegaly, and can be treated with medications, blood transfusions or bone‑marrow transplants.
Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Related signals
- ASH 2024: New Research, Data Drive Progress in Myelofibrosis
- Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK inhibitors
- Population Pharmacokinetics and Exposure‑Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis
- SOHO 2026: Imetelstat Efficacy in Myelofibrosis - GERN
- Current treatments, practical management, and emerging investigational therapies for myelofibrosis